Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 1.19
MDT's Cash to Debt is ranked higher than
59% of the 384 Companies
in the Global Medical Devices industry.

( Industry Median: 4.48 vs. MDT: 1.19 )
MDT' s 10-Year Cash to Debt Range
Min: 0.21   Max: 7.76
Current: 1.19

0.21
7.76
Equity to Asset 0.51
MDT's Equity to Asset is ranked higher than
57% of the 367 Companies
in the Global Medical Devices industry.

( Industry Median: 0.65 vs. MDT: 0.51 )
MDT' s 10-Year Equity to Asset Range
Min: 0.48   Max: 0.79
Current: 0.51

0.48
0.79
Interest Coverage 10.06
MDT's Interest Coverage is ranked higher than
51% of the 204 Companies
in the Global Medical Devices industry.

( Industry Median: 117.58 vs. MDT: 10.06 )
MDT' s 10-Year Interest Coverage Range
Min: 6.58   Max: 352.69
Current: 10.06

6.58
352.69
F-Score: 5
Z-Score: 4.00
M-Score: -2.76
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 22.42
MDT's Operating margin (%) is ranked higher than
94% of the 372 Companies
in the Global Medical Devices industry.

( Industry Median: 6.25 vs. MDT: 22.42 )
MDT' s 10-Year Operating margin (%) Range
Min: 16.71   Max: 66.79
Current: 22.42

16.71
66.79
Net-margin (%) 18.02
MDT's Net-margin (%) is ranked higher than
94% of the 372 Companies
in the Global Medical Devices industry.

( Industry Median: 4.71 vs. MDT: 18.02 )
MDT' s 10-Year Net-margin (%) Range
Min: 11.03   Max: 22.78
Current: 18.02

11.03
22.78
ROE (%) 15.76
MDT's ROE (%) is ranked higher than
92% of the 368 Companies
in the Global Medical Devices industry.

( Industry Median: 5.93 vs. MDT: 15.76 )
MDT' s 10-Year ROE (%) Range
Min: 12.38   Max: 33.4
Current: 15.76

12.38
33.4
ROA (%) 8.08
MDT's ROA (%) is ranked higher than
88% of the 382 Companies
in the Global Medical Devices industry.

( Industry Median: 3.43 vs. MDT: 8.08 )
MDT' s 10-Year ROA (%) Range
Min: 8.08   Max: 24.21
Current: 8.08

8.08
24.21
ROC (Joel Greenblatt) (%) 70.42
MDT's ROC (Joel Greenblatt) (%) is ranked higher than
96% of the 381 Companies
in the Global Medical Devices industry.

( Industry Median: 13.35 vs. MDT: 70.42 )
MDT' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 44.94   Max: 136.71
Current: 70.42

44.94
136.71
Revenue Growth (%) 5.40
MDT's Revenue Growth (%) is ranked higher than
74% of the 301 Companies
in the Global Medical Devices industry.

( Industry Median: 5.00 vs. MDT: 5.40 )
MDT' s 10-Year Revenue Growth (%) Range
Min: 4.2   Max: 17.9
Current: 5.4

4.2
17.9
EBITDA Growth (%) 3.50
MDT's EBITDA Growth (%) is ranked higher than
80% of the 282 Companies
in the Global Medical Devices industry.

( Industry Median: -3.60 vs. MDT: 3.50 )
MDT' s 10-Year EBITDA Growth (%) Range
Min: -15.5   Max: 45.4
Current: 3.5

-15.5
45.4
EPS Growth (%) 2.30
MDT's EPS Growth (%) is ranked higher than
76% of the 262 Companies
in the Global Medical Devices industry.

( Industry Median: -1.70 vs. MDT: 2.30 )
MDT' s 10-Year EPS Growth (%) Range
Min: -4.7   Max: 27.1
Current: 2.3

-4.7
27.1
» MDT's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

MDT Guru Trades in Q3 2013

Jim Simons 1,026,700 sh (+2667.39%)
Pioneer Investments 844,648 sh (+136.09%)
Joel Greenblatt 193,635 sh (+92.19%)
Ray Dalio 45,545 sh (+56.81%)
Paul Tudor Jones 14,000 sh (+25%)
Chuck Royce 112,800 sh (+22.74%)
John Buckingham 17,471 sh (+7.6%)
Jeremy Grantham 10,124,082 sh (+4.99%)
John Hussman 205,000 sh (+2.5%)
Manning & Napier Advisors, Inc 361,404 sh (+1.66%)
James Barrow 32,327,133 sh (+0.25%)
Vanguard Health Care Fund 10,532,800 sh (unchged)
Jean-Marie Eveillard 8,000 sh (unchged)
Bill Nygren 4,385,000 sh (unchged)
Chris Davis Sold Out
HOTCHKIS & WILEY 1,749,300 sh (-0.5%)
Diamond Hill Capital 5,313,585 sh (-0.82%)
PRIMECAP Management 31,844,221 sh (-0.89%)
Jeff Auxier 151,720 sh (-1.33%)
Arnold Van Den Berg 265,963 sh (-1.95%)
Bill Frels 4,088,239 sh (-2.27%)
Dodge & Cox 9,591,376 sh (-2.66%)
Ken Fisher 7,387 sh (-4.23%)
John Keeley 34,120 sh (-29.28%)
Scott Black 14,198 sh (-33.36%)
Steven Cohen 16,310 sh (-78.87%)
» More
Q4 2013

MDT Guru Trades in Q4 2013

Scott Black 41,683 sh (+193.58%)
Ray Dalio 132,345 sh (+190.58%)
Paul Tudor Jones 32,191 sh (+129.94%)
Jim Simons 1,512,400 sh (+47.31%)
John Hussman 250,000 sh (+21.95%)
Chuck Royce 133,200 sh (+18.09%)
Steven Cohen 18,543 sh (+13.69%)
John Buckingham 18,507 sh (+5.93%)
Pioneer Investments 877,947 sh (+3.94%)
James Barrow 32,642,450 sh (+0.98%)
Jeremy Grantham 10,186,365 sh (+0.62%)
John Keeley 34,160 sh (+0.12%)
Bill Frels 4,090,802 sh (+0.06%)
Jean-Marie Eveillard 8,000 sh (unchged)
Bill Nygren 4,385,000 sh (unchged)
Jeff Auxier 151,720 sh (unchged)
Vanguard Health Care Fund 10,532,800 sh (unchged)
HOTCHKIS & WILEY 1,740,800 sh (-0.49%)
PRIMECAP Management 31,614,803 sh (-0.72%)
Diamond Hill Capital 5,272,970 sh (-0.76%)
Ken Fisher 7,020 sh (-4.97%)
Dodge & Cox 9,019,976 sh (-5.96%)
Manning & Napier Advisors, Inc 202,619 sh (-43.94%)
Arnold Van Den Berg 133,283 sh (-49.89%)
Joel Greenblatt 90,485 sh (-53.27%)
» More
Q1 2014

MDT Guru Trades in Q1 2014

Steven Cohen 153,212 sh (+726.25%)
Joel Greenblatt 244,649 sh (+170.38%)
HOTCHKIS & WILEY 2,066,800 sh (+18.73%)
Vanguard Health Care Fund 11,336,900 sh (+7.63%)
Bill Nygren 4,585,000 sh (+4.56%)
Scott Black 43,053 sh (+3.29%)
John Buckingham 18,828 sh (+1.73%)
Diamond Hill Capital 5,349,218 sh (+1.45%)
Bill Frels 4,124,297 sh (+0.82%)
Manning & Napier Advisors, Inc 203,440 sh (+0.41%)
John Keeley 34,160 sh (unchged)
John Hussman 250,000 sh (unchged)
Jean-Marie Eveillard Sold Out
Arnold Van Den Berg Sold Out
PRIMECAP Management 31,570,188 sh (-0.14%)
Jim Simons 1,507,100 sh (-0.35%)
Dodge & Cox 8,982,143 sh (-0.42%)
Jeff Auxier 150,720 sh (-0.66%)
Ken Fisher 6,853 sh (-2.38%)
James Barrow 31,718,209 sh (-2.83%)
Chuck Royce 128,800 sh (-3.3%)
Pioneer Investments 809,321 sh (-7.82%)
Jeremy Grantham 7,050,459 sh (-30.79%)
Ray Dalio 87,345 sh (-34%)
Paul Tudor Jones 11,100 sh (-65.52%)
» More
Q2 2014

MDT Guru Trades in Q2 2014

Manning & Napier Advisors, Inc Sold Out
Ken Fisher 6,015 sh (-12.23%)
» More
» Details

Insider Trades

Latest Guru Trades with MDT

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Arnold Van Den Berg 2014-03-31 Sold Out 0.72%$53.6 - $60.84 $ 62.98%0
Joel Greenblatt 2014-03-31 Add 170.38%0.14%$53.6 - $60.84 $ 62.98%244649
Vanguard Health Care Fund 2014-03-31 Add 7.63%0.14%$53.6 - $60.84 $ 62.98%11336900
Ray Dalio 2014-03-31 Reduce -34%0.02%$53.6 - $60.84 $ 62.98%87345
Jean-Marie Eveillard 2014-03-31 Sold Out $53.6 - $60.84 $ 62.98%0
Arnold Van Den Berg 2013-12-31 Reduce -49.89%0.7%$52.46 - $58.84 $ 62.911%133283
Joel Greenblatt 2013-12-31 Reduce -53.27%0.18%$52.46 - $58.84 $ 62.911%90485
John Hussman 2013-12-31 Add 21.95%0.18%$52.46 - $58.84 $ 62.911%250000
Scott Black 2013-12-31 Add 193.58%0.17%$52.46 - $58.84 $ 62.911%41683
Ray Dalio 2013-12-31 Add 190.58%0.04%$52.46 - $58.84 $ 62.911%132345
Joel Greenblatt 2013-09-30 Add 92.19%0.16%$51.51 - $55.88 $ 62.917%193635
Scott Black 2013-09-30 Reduce -33.36%0.04%$51.51 - $55.88 $ 62.917%14198
John Keeley 2013-09-30 Reduce -29.28%0.01%$51.51 - $55.88 $ 62.917%34120
Ray Dalio 2013-09-30 Add 56.81%0.01%$51.51 - $55.88 $ 62.917%45545
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Medtronic Inc

Bill Frels Comments on Medtronic Inc - Jun 25, 2014

Healthcare company Medtronic, Inc. (MDT) also finished the quarter as a top five contributor to the Fund, gaining 7.23%. While emerging market revenue proved scarce for most industries during the quarter, Medtronic increased its share of revenue from the developing world by 15%, which represented 12% of the company’s revenue.



From Bill Frels' Mairs & Power Balance Fund First Quarter 2014 Commentary.



Check out Bill Frels latest stock trades

Diamond Hill Capital Comments on Medtronic Inc - Oct 24, 2012

Medical device manufacturer Medtronic, Inc. (MDT) reported results that were in-line with Wall Street analysts' expectations but demonstrated sequential improvement in underlying trends, including sales growth excluding foreign exchange affects. Medtronic's growth prospects benefited from market share gains in the Drug-eluting Stent (DES) business, with a better than expected launch of the Resolute Integrity stent. A focus on the international opportunities, specifically China, should also improve long-term potential.

From Diamond Hill Capital's third quarter Select Fund Commentary.


Check out Diamond Hill Capital latest stock trades

Top Ranked Articles about Medtronic Inc

Bill Frels Comments on Medtronic Inc
Healthcare company Medtronic, Inc. (MDT) also finished the quarter as a top five contributor to the Fund, gaining 7.23%. While emerging market revenue proved scarce for most industries during the quarter, Medtronic increased its share of revenue from the developing world by 15%, which represented 12% of the company’s revenue. Read more...
Bill Frels' Mairs & Power Balance Fund First Quarter 2014 Commentary
March 31, 2014 Read more...
Diamond Hill Capital's Top Five Holdings
Over the past quarter Diamond Hill Capital added seven new stocks to its portfolio, bringing the total number of stocks to 152 valued at $10.96 billion. The fund manages five long-only equity strategies, three alternative equity strategies and a fixed income strategy. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 20.90
MDT's P/E(ttm) is ranked higher than
91% of the 413 Companies
in the Global Medical Devices industry.

( Industry Median: 67.60 vs. MDT: 20.90 )
MDT' s 10-Year P/E(ttm) Range
Min: 10.14   Max: 43.51
Current: 20.9

10.14
43.51
P/B 3.24
MDT's P/B is ranked higher than
70% of the 413 Companies
in the Global Medical Devices industry.

( Industry Median: 3.46 vs. MDT: 3.24 )
MDT' s 10-Year P/B Range
Min: 2.03   Max: 7.1
Current: 3.24

2.03
7.1
P/S 3.75
MDT's P/S is ranked higher than
64% of the 413 Companies
in the Global Medical Devices industry.

( Industry Median: 3.30 vs. MDT: 3.75 )
MDT' s 10-Year P/S Range
Min: 1.92   Max: 7.25
Current: 3.75

1.92
7.25
PFCF 13.95
MDT's PFCF is ranked higher than
95% of the 413 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. MDT: 13.95 )
MDT' s 10-Year PFCF Range
Min: 9.2   Max: 70.14
Current: 13.95

9.2
70.14
EV-to-EBIT 16.18
MDT's EV-to-EBIT is ranked higher than
90% of the 413 Companies
in the Global Medical Devices industry.

( Industry Median: 44.56 vs. MDT: 16.18 )
MDT' s 10-Year EV-to-EBIT Range
Min: 8.8   Max: 23.8
Current: 16.18

8.8
23.8
PEG 7.21
MDT's PEG is ranked higher than
86% of the 413 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. MDT: 7.21 )
MDT' s 10-Year PEG Range
Min: 1.06   Max: 19.93
Current: 7.21

1.06
19.93
Shiller P/E 20.57
MDT's Shiller P/E is ranked higher than
96% of the 413 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. MDT: 20.57 )
MDT' s 10-Year Shiller P/E Range
Min: 12.16   Max: 53.47
Current: 20.57

12.16
53.47
Current Ratio 3.82
MDT's Current Ratio is ranked higher than
78% of the 380 Companies
in the Global Medical Devices industry.

( Industry Median: 2.92 vs. MDT: 3.82 )
MDT' s 10-Year Current Ratio Range
Min: 0.88   Max: 4.52
Current: 3.82

0.88
4.52
Quick Ratio 3.51
MDT's Quick Ratio is ranked higher than
82% of the 380 Companies
in the Global Medical Devices industry.

( Industry Median: 2.16 vs. MDT: 3.51 )
MDT' s 10-Year Quick Ratio Range
Min: 0.69   Max: 4.09
Current: 3.51

0.69
4.09

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.82
MDT's Dividend Yield is ranked higher than
72% of the 178 Companies
in the Global Medical Devices industry.

( Industry Median: 1.26 vs. MDT: 1.82 )
MDT' s 10-Year Dividend Yield Range
Min: 0.56   Max: 2.93
Current: 1.82

0.56
2.93
Dividend Payout 0.40
MDT's Dividend Payout is ranked higher than
93% of the 413 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. MDT: 0.40 )
MDT' s 10-Year Dividend Payout Range
Min: 0.14   Max: 0.41
Current: 0.4

0.14
0.41
Dividend growth (3y) 7.60
MDT's Dividend growth (3y) is ranked higher than
79% of the 91 Companies
in the Global Medical Devices industry.

( Industry Median: 7.60 vs. MDT: 7.60 )
MDT' s 10-Year Dividend growth (3y) Range
Min: 7.6   Max: 28.4
Current: 7.6

7.6
28.4
Yield on cost (5-Year) 2.64
MDT's Yield on cost (5-Year) is ranked higher than
77% of the 178 Companies
in the Global Medical Devices industry.

( Industry Median: 1.30 vs. MDT: 2.64 )
MDT' s 10-Year Yield on cost (5-Year) Range
Min: 0.73   Max: 4.31
Current: 2.64

0.73
4.31
Share Buyback Rate 2.10
MDT's Share Buyback Rate is ranked higher than
94% of the 280 Companies
in the Global Medical Devices industry.

( Industry Median: -0.90 vs. MDT: 2.10 )
MDT' s 10-Year Share Buyback Rate Range
Min: 2.6   Max: -8.5
Current: 2.1

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 9.59
MDT's Price/Tangible Book is ranked higher than
58% of the 413 Companies
in the Global Medical Devices industry.

( Industry Median: 5.99 vs. MDT: 9.59 )
MDT' s 10-Year Price/Tangible Book Range
Min: 8.37   Max: 40.91
Current: 9.59

8.37
40.91
Price/DCF (Projected) 1.09
MDT's Price/DCF (Projected) is ranked higher than
97% of the 413 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. MDT: 1.09 )
MDT' s 10-Year Price/DCF (Projected) Range
Min: 0.77   Max: 6.95
Current: 1.09

0.77
6.95
Price/Median PS Value 1.06
MDT's Price/Median PS Value is ranked higher than
76% of the 413 Companies
in the Global Medical Devices industry.

( Industry Median: 1.20 vs. MDT: 1.06 )
MDT' s 10-Year Price/Median PS Value Range
Min: 0.7   Max: 3.57
Current: 1.06

0.7
3.57
Price/Peter Lynch Fair Value 2.23
MDT's Price/Peter Lynch Fair Value is ranked higher than
94% of the 413 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. MDT: 2.23 )
MDT' s 10-Year Price/Peter Lynch Fair Value Range
Min: 1.23   Max: 6.46
Current: 2.23

1.23
6.46
Price/Graham Number 2.96
MDT's Price/Graham Number is ranked higher than
80% of the 413 Companies
in the Global Medical Devices industry.

( Industry Median: 9.06 vs. MDT: 2.96 )
MDT' s 10-Year Price/Graham Number Range
Min: 2.12   Max: 10.04
Current: 2.96

2.12
10.04
Earnings Yield (Greenblatt) 6.20
MDT's Earnings Yield (Greenblatt) is ranked higher than
82% of the 287 Companies
in the Global Medical Devices industry.

( Industry Median: 4.90 vs. MDT: 6.20 )
MDT' s 10-Year Earnings Yield (Greenblatt) Range
Min: 4.2   Max: 11.3
Current: 6.2

4.2
11.3
Forward Rate of Return (Yacktman) 13.99
MDT's Forward Rate of Return (Yacktman) is ranked higher than
90% of the 306 Companies
in the Global Medical Devices industry.

( Industry Median: 0.97 vs. MDT: 13.99 )
MDT' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 3.3   Max: 23.6
Current: 13.99

3.3
23.6

Business Description

Industry: Medical Devices » Medical Devices
Compare:SYK, SMA, ZMH, STJ, EW » details
Traded in other countries:MDT.Germany
Medtronic, Inc., was incorporated as a Minnesota corporation in 1957. The Company is engaged in providing medical technology- alleviating pain, restoring health, and extending life for people. The Company develops, manufactures, and markets its medical devices in more than 140 countries. Its products include those for cardiac rhythm disorders, cardiovascular disease, neurological disorders, spinal conditions and musculoskeletal trauma, urological and digestive disorders, diabetes, and ear, nose, and throat conditions. The Company's operating segments are: Cardiac and Vascular Group; and Restorative Therapies Group. Cardiac and Vascular Group includes Cardiac Rhythm Disease Management (CRDM) and CardioVascular. Restorative Therapies Group includes Spinal, Neuromodulation, Diabetes, and Surgical Technologies. CRDM develops, manufactures, and markets products for the diagnosis, treatment, and management of heart rhythm disorders and heart failure, including implantable devices, leads and delivery systems, products for the treatment of atrial fibrillation (AF), and information systems for the management of patients with CRDM devices. CardioVascular is composed of the following three businesses: Coronary, Endovascular and Peripheral, and Structural Heart. Its Spinal business develops, manufactures, and markets a comprehensive line of medical devices and implants used in the treatment of the spine and musculoskeletal system. Its Neuromodulation business develops, manufactures, and markets medical devices for the treatment of chronic pain, movement disorders, psychological disorders, and urological, fecal, and gastroenterological disorders. Its Diabetes business develops, manufactures, and markets advanced, integrated diabetes management solutions that include insulin pump therapy, continuous glucose monitoring systems, and therapy management software. Its Surgical Technologies business develops, manufactures, and markets products and therapies to treat diseases and conditions of the ear, nose, and throat (ENT) and certain neurological disorders. In addition, the business develops, manufactures, and markets image-guided surgery and intra-operative imaging systems that facilitate surgical planning during precision cranial, spinal, sinus, and orthopedic surgeries. Its main customers include hospitals, clinics, third-party health care providers, distributors, and other institutions, including governmental health care programs and group purchasing organizations. Its competitors are St. Jude Medical, Inc., Boston Scientific Corporation, Biotronik, Inc., Sorin Group, Abbott Laboratories and Boston Scientific, GETINGE AB, and Terumo Medical Corporation. The Company's medical devices are subject to regulation by numerous government agencies, including the U.S.
» More Articles for MDT

Headlines

Articles On GuruFocus.com
Bill Frels Comments on Medtronic Inc Jun 25 2014 
Bill Frels' Mairs & Power Balance Fund First Quarter 2014 Commentary Jun 25 2014 
Medtronic: A Lesson on Reasonableness Despite New Highs Jun 05 2014 
Outlook for June 2014 Jun 02 2014 
Becton, Dickinson and Co. (BDX) Dividend Stock Analysis May 30 2014 
Oakmark’s Bill Nygren's Top Holdings Led by Bank of America and Oracle May 29 2014 
Medtronic: This Medical Apparatus Maker Can Boost Your Portfolio May 26 2014 
Outlook for May 2014 May 01 2014 
We Are Confident About Baxter's Plan to Create Two Separate Health Care Companies Mar 28 2014 
Top Owned Health Care Stocks of the Fourth Quarter Mar 07 2014 

More From Our Partners
Covidien Beats on Q3 Earnings but Revenues Miss - Analyst Blog Jul 25 2014 - ZACKS

More From Other Websites
Walgreens eyes loophole end run around taxes Jul 26 2014
Ireland does not promote or seek corporate tax-avoidance deals: minister Jul 25 2014
MARK CUBAN: If Your Company Is Moving For Tax Reasons, I'm Selling Your Stock Jul 25 2014
Obama Goes On The Attack Against Companies Doing Inversions To Move To Countries Where They Pay Less... Jul 25 2014
Obama calls on Congress to end inversion deals, NY Times reports Jul 25 2014
Obama steps up criticism of tax inversions Jul 24 2014
Some Senate Democrats Wary as Obama Fights Tax Inversions Jul 24 2014
Obama to Make Campaign Pitch on Corporate Tax Avoidance Jul 24 2014
Narrow Push on Overseas Tax Breaks Advances in Senate Jul 23 2014
Trader sees Medtronic holding firm Jul 23 2014
[video] Faber Report: Inversion train rolling Jul 23 2014
Tax inversions allow firms to avoid state taxes Jul 21 2014
AbbVie Gets Its 'Tax Break' In Shire Jul 21 2014
AbbVie, Shire agree on $55B combination Jul 18 2014
AbbVie, Shire agree on $55B combination Jul 18 2014
MEDTRONIC INC Files SEC form 8-K, Other Events Jul 17 2014
Hatch Open to Some Near-Term Steps Addressing Inversions Jul 17 2014
Congress And Tax Inversions: A Wall Streeter's Take On 2014 Jul 16 2014
Abbott, St. Jude Top Views, But Stocks Under Pressure Jul 16 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide